About NCL
NCL is a venture capital firm founded in 2015. It is primarily based out of London, United Kingdom. As of Jun 2020, NCL has invested in 9 companies. It primarily invests in Series A round in Israel based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Curesponse Overall, NCL portfolio has seen 1 IPO, namely TC Biopharm. aMoon co-invest with NCL, sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
Portfolio IPOs
Portfolio Soonicorns
NCL's List of Top Investments
NCL has a portfolio of 9 companies. Their most notable investments are in Azadyne and Curesponse.Their portfolio spans across United Kingdom, United States and Israel. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Seed, Series A stages. Here is the list of top investments by NCL:1. TC Biopharm
Developer of T-cell therapies for cancer and infectious disease treatment. The company is developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.
Key facts about TC Biopharm
- Founded Year: 2013
- Location: Edinburgh (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2018
- Stage: Public
- Total Funding till date: $10.6M
- Employee Count: 15 as on Jun 30, 2026
- Investors: Nipro, Syndicate Room and 8 Others
- Latest Funding Round: Post IPO, Nov 28, 2022, $*****
- Highlight: Public
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Key facts about Centauri Therapeutics
- Founded Year: 2014
- Location: Kent (United Kingdom)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $73M
- Employee Count: 24 as on May 31, 2026
- Investors: Novo Holdings, Boehringer Ingelheim Venture Fund and 32 Others
- Latest Funding Round: Series A, Feb 24, 2026, $*****
- Highlight: Editors' Pick
3. Sana
Developer of a wearable sleep inducer for individuals. It offers a smart sleeping mask to manage sleeping and neurological disorders. The wearable device measures sleep and health data over time that is transferred to a platform. The software uses the measured data to analyze and provide tailored programs on deep relaxation for sleeping and aid patients in improving neurological disorders.
Key facts about Sana
- Founded Year: 2015
- Location: Lafayette (United States)
- Stage: Seed
- Total Funding till date: $13.8M
- Employee Count: 29 as on Jun 30, 2026
- Investors: Founders Fund, Flucas Ventures and 34 Others
- Latest Funding Round: Seed, Jul 30, 2020, $*****
- Highlight: Editors' Pick
Ampersand Health offers personalized digital therapy platform for long-term inflammatory conditions like IBD and Arthritis, help prolong periods of remission, and provide support in the self-management of long-term conditions.
Key facts about Ampersand Health
- Founded Year: 2017
- Location: London (United Kingdom)
- Stage: Seed
- Employee Count: 4 as on May 31, 2025
- Investors: Crista Galli Ventures, Conduit Connect and 11 Others
- Latest Funding Round: Seed, May 25, 2022, $*****
5. Emteq Labs
Developer of emotion sensing and analytics platform. It provides users with hardware sensors and readers for multi-modal biometrics like fingerprint, face, and eye scans. Its features include data management, cloud-data analytics, and comprehensive insights.
Key facts about Emteq Labs
- Founded Year: 2015
- Location: Brighton (United Kingdom)
- Valuation: $*****
- Stage: Seed
- Total Funding till date: $3.23M
- Employee Count: 23 as on May 31, 2026
- Investors: NCL and 5 Others
- Latest Funding Round: Seed, Apr 25, 2023, $*****
NCL's Year-on-Year Investment Trends
Its most recent first time investment was in Curesponse.NCL's Investments by Stage
NCL has made 1 investment in Seed stage with an average round size of $1.97M and 1 investment in Series A stage with an average round size of $6M.NCL's Investments by Sector
NCL has a portfolio focused on Life Sciences. Notably, it has invested in 9 Tech companies, 8 Enterprise (B2B) companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Software.NCL's Investments by Geography
NCL has made most investments in Israel (1), followed by United Kingdom where it has made 1 investment.NCL's recent investments
NCL has not made any investment in 2026 so far.Here are the most recent investments by NCL:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 05, 2020 | Israel | Series A | 1129 | ||
Mar 27, 2019 | United Kingdom | Seed | 5603 | - |
IPOs and Publicly Listed companies in NCL's Portfolio
1 of NCL's portfolio company became public - TC Biopharm. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2022 at marketcap of $119MHere are NCL's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 11, 2022 | - | - | 9367 |
Co-investors of NCL
Over the past 7 years, one investor has co-invested in NCL's portfolio companies. This includes funds and angels.
- Top Co-investors of NCL: aMoon entered a company along with NCL.
Recent News related to NCL
•
Slim acquires oil cake that belonged to Bailleresemmanuelameth.com.mx•Dec 19, 2023•PetroBal, Alert Technology, NCL Innovations, NCL
•
Asbestos detection firm secures new investmentInsider Media•Mar 08, 2017•Alert Technology, NCL Innovations, NCL
